Interferon Signaling in Estrogen Receptor–positive Breast Cancer: A Revitalized Topic
Endocrinology · 01.01.2022 · 163 (1)
DOI: 10.1210/endocr/bqab235 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrinology, online erschienen am 16.11.2021. Verfasst von Xiaoyong Fu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 193 Literaturangaben. Gefördert von: Department of Defense Breast Cancer Research Program, Cancer Prevention and Research Institute of Texas, Breast Cancer Research Foundation.
Abstract (Originalsprache)
Cancer immunology is the most rapidly expanding field in cancer research, with the importance of immunity in cancer pathogenesis now well accepted including in the endocrine-related cancers. The immune system plays an essential role in the development of ductal and luminal epithelial differentiation in the mammary gland. Originally identified as evolutionarily conserved antipathogen cytokines, interferons (IFNs) have shown important immune-modulatory and antineoplastic properties when administered to patients with various types of cancer, including breast cancer. Recent studies have drawn attention to the role of tumor- and stromal-infiltrating lymphocytes in dictating therapy response and outcome of breast cancer patients, which, however, is highly dependent on the breast cancer subtype. The emerging role of tumor cell–inherent IFN signaling in the subtype-defined tumor microenvironment could influence therapy response with protumor activities in breast cancer. Here we review evidence with new insights into tumor cell–intrinsic and tumor microenvironment–derived IFN signaling, and the crosstalk of IFN signaling with key signaling pathways in estrogen receptor–positive (ER+) breast cancer. We also discuss clinical implications and opportunities exploiting IFN signaling to treat advanced ER+ breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA.
- Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA.
- Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA.
- Department of Clinical Medicine and Surgery, University of Naples Federico II, 80138 Naples, Italy.
- Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA.
ORCID-Profile: Xiaoyong Fu
Förderung
- Department of Defense Breast Cancer Research Program
- Cancer Prevention and Research Institute of Texas
- Breast Cancer Research Foundation
Zitieren
APA
Fu, X., De Angelis, C., & Schiff, R. (2022). Interferon Signaling in Estrogen Receptor–positive Breast Cancer: A Revitalized Topic. Endocrinology, 163(1). https://doi.org/10.1210/endocr/bqab235
Vancouver
Fu X, De Angelis C, Schiff R. Interferon Signaling in Estrogen Receptor–positive Breast Cancer: A Revitalized Topic. Endocrinology. 2022;163(1). doi:10.1210/endocr/bqab235
BibTeX
@article{Fu2022,
author = {Fu, Xiaoyong and De Angelis, Carmine and Schiff, Rachel},
title = {Interferon Signaling in Estrogen Receptor–positive Breast Cancer: A Revitalized Topic},
journal = {Endocrinology},
year = {2022},
volume = {163},
number = {1},
doi = {10.1210/endocr/bqab235}
}
EUVIMED